Juva Research is Juva Life’s therapeutics division which has begun conducting medicinal cannabis-based product research. Using IRB-approved longitudinal registry studies and their collection of real-world data with patient-reported and clinical outcomes, Juva Research will develop a wide range of pharmacy-grade cannabis products that are consistent, rigorously-tested and meticulously formulated.

In March of 2021, Juva enrolled the first human subject into its IMPACT Study, a first step in establishing the clinical methodology to efficiently gauge the clinical effect of various cannabis-based formulations.

Initial clinical indications being targeted include pain, sleep, appetite, among others. Data to be recorded includes:

• Basic demographics of patients using cannabis-based medicaments.
• Disease diagnoses and symptoms for which patients are seeking management.
• Cannabinoid formulation, chemical composition, amount (in milligrams), dose and utilization.
• Patient Reported Outcomes (PRO) for sleep, pain, appetite, and other indications
• Concomitant use of other anti-inflammatory or analgesic medications
• Overall impact on clinical or patient treatment plans.

This work is critical to make progress towards the development of new, safe, and evidence-based cannabis products which target un-met medical needs.